US Patent

US8691938 — Anti-viral compounds

Composition of Matter · Assigned to AbbVie Inc · Expires 2032-04-13 · 6y remaining

Vulnerability score 10/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects compounds that inhibit the replication of the Hepatitis C virus and processes for making and using these compounds.

USPTO Abstract

Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Drugs covered by this patent

Patent Metadata

Patent number
US8691938
Jurisdiction
US
Classification
Composition of Matter
Expires
2032-04-13
Drug substance claim
Yes
Drug product claim
Yes
Assignee
AbbVie Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.